DEAR DR. ROACH: I am a 70-year old woman with a prior history of asymptomatic atrial fibrillation (AFib). I’ve been in normal sinus rhythm since having two catheter ablations in 2018. I take Eliquis ...

Any leakage around a percutaneous left atrial appendage (LAA) implant, no matter how small, predicted strokes and other thrombotic events after the procedure, according to a retrospective study. In ...

MARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary ...

SAN FRANCISCO — Thirteen months after percutaneous left atrial appendage closure (LAAC), outcomes did not differ whether closure was performed using the Amulet (Abbott Cardiovascular) or the Watchman ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Rates of patency and device-related thrombus were ...

NEW ORLEANS -- It may be reasonable for people with atrial fibrillation (Afib) to undergo percutaneous left atrial appendage (LAA) closure even if long-term anticoagulation is an alternative, ...

ROCHESTER, MN – The PREVAIL study, a clinical trial evaluating the safety of the Watchman (Boston Scientific) left atrial appendage (LAA) closure device in the treatment of patients with nonvalvular ...

Columbus Regional Health Heart & Vascular announced that its cardiovascular services team recently completed its 100th Watchman™ procedure, which treats patients with atrial fibrillation (AFib).

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

Dear Dr. Roach: I am a 70-year old woman with a prior history of asymptomatic atrial fibrillation (AFib). I've been in normal sinus rhythm since having two catheter ablations in 2018. I take Eliquis ...

Boston ScientificBSX stock tumbled to a two-year low Monday on mixed test results for its Watchman device in patients at risk of having a stroke. Watchman FLX involves a one-time, minimally invasive ...